Epidermolysis Bullosa Therapeutics Market - Large Number Of Drugs In The Pipeline Is Providing Growth Opportunities For The Players Including Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc., Scioderm, Inc., TWi Biotechnology Inc. etc.

Epidermolysis Bullosa (EB) is a rare, genetic disorder of skin tissues. People suffering from EB have fragile skin, which is susceptible to blisters leading to wounds that are difficult to heal. Symptoms related to this disorder includes, blistering of skin, deformity or loss of fingernails and toenails, internal blistering including on the throat, esophagus, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring, and hair loss (scarring alopecia).

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2214

Epidermolysis Bullosa Therapeutics Market Drivers

Development of various pipeline drugs for treatment of EB is a major factor expected to drive the epidermolysis bullosa therapeutics market growth. For instance, Fibrocell Technologies, Inc. is undergoing clinical trial for its drug FCX-007 for the treatment of EB. This drug is under clinical phase II and is expected to be completed in December 2033. TWi Biotechnology, Inc. is conducting phase II clinical trial for the drug AC-203 to treat skin lesions in EB and is expected to complete the study in February 2019.

Amryt Research Limited is conducting clinical trial phase III for its drug Oleogel-S10, which is intended for the treatment of wounds in EB that is expected to complete in September 2020. Furthermore, in May 2018, Abeona Therapeutics Inc. announced updated clinical data from the Phase I/II trial of EB-101, a gene-corrected skin graft cell therapy for patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). The EB-101 has been granted Regenerative Medicine Advanced Therapy (RMAT) designation in January 2018, Orphan Drug Designation and Rare Pediatric Disease Designation from the US Food and Drug Administration (US FDA) and European Medicines Agency (EMA) in 2017.

Epidermolysis Bullosa Therapeutics Market – Regional Analysis

On the basis of region, the global epidermolysis bullosa therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America region is expected to witness growth in the EB therapeutics market due to inorganic growth strategies adopted by key players. For instance, in August 2015, Amicus Therapeutics, a biotechnology company involved in developing drugs for orphan diseases acquired Scioderm, Inc., a company involved in developing innovative therapies for treating diseases. This acquisition aims to accelerate clinical development of Zorblisa, drug of Amicus Therapeutics, which is under preclinical investigation for commercialization, for the treatment of epidermolysis bullosa.

Key players operating in epidermolysis bullosa therapeutics market include Birken AG, Fibrocell Science, Inc., RegeneRx Biopharmaceuticals, Inc., GlaxoSmithKline Plc., InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., Scioderm, Inc., Stratatech Corporation, TWi Biotechnology Inc., Amryt Research Limited, and WAVE Life Sciences Ltd.

Request For Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/2214

Epidermolysis Bullosa Therapeutics Market – Taxonomy

By Drugs:

EB-101
Oleogel-S10
Others

By Region:

North America
Europe
Asia Pacific
Latin America
Middle East
Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.